{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T01:02:23Z","timestamp":1772931743624,"version":"3.50.1"},"reference-count":54,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Covalent Bruton tyrosine kinase (BTK) inhibitors, such as ibrutinib, have proven to be highly beneficial in the treatment of chronic lymphocytic leukemia (CLL). Interestingly, the off-target inhibition of IL-2-inducible T-cell kinase (ITK) by ibrutinib may also play a role in modulating the tumor microenvironment, potentially enhancing the treatment benefit. However, resistance to covalently binding BTK inhibitors can develop as the result of a mutation in cysteine 481 of BTK (C481S), which prevents irreversible binding of the drugs. In the present study we performed preclinical characterization of vecabrutinib, a next-generation noncovalent BTK inhibitor that has ITK-inhibitory properties similar to those of ibrutinib. Unlike ibrutinib and other covalent BTK inhibitors, vecabrutinib showed retention of the inhibitory effect on C481S BTK mutants in\u00a0vitro, similar to that of wild-type BTK. In the murine E\u03bc-TCL1 adoptive transfer model, vecabrutinib reduced tumor burden and significantly improved survival. Vecabrutinib treatment led to a decrease in CD8+ effector and memory T-cell populations, whereas the naive populations were increased. Of importance, vecabrutinib treatment significantly reduced the frequency of regulatory CD4+ T cells in\u00a0vivo. Unlike ibrutinib, vecabrutinib treatment showed minimal adverse impact on the activation and proliferation of isolated T cells. Lastly, combination treatment with vecabrutinib and venetoclax augmented treatment efficacy, significantly improved survival, and led to favorable reprogramming of the microenvironment in the murine E\u03bc-TCL1 model. Thus, noncovalent BTK\/ITK inhibitors, such as vecabrutinib, may be efficacious in C481S BTK mutant CLL while preserving the T-cell immunomodulatory function of ibrutinib.<\/jats:p>","DOI":"10.1182\/blood.2021011516","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T21:00:28Z","timestamp":1634763628000},"page":"859-875","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Evaluation of vecabrutinib as a model for noncovalent BTK\/ITK inhibition for treatment of chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6188-1652","authenticated-orcid":false,"given":"Billy Michael Chelliah","family":"Jebaraj","sequence":"first","affiliation":[{"name":"Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi Priyadharshini","family":"Dheenadayalan","sequence":"additional","affiliation":[{"name":"Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7243-6829","authenticated-orcid":false,"given":"Sascha","family":"Endres","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Toxicology, Ulm University, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7061-5690","authenticated-orcid":false,"given":"Philipp M.","family":"Roessner","sequence":"additional","affiliation":[{"name":"Molecular Genetics, German Cancer Research Center, Heidelberg, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Seyfried","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Walliser","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Toxicology, Ulm University, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wist","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Toxicology, Ulm University, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-2291","authenticated-orcid":false,"given":"Jialei","family":"Qi","sequence":"additional","affiliation":[{"name":"Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Tausch","sequence":"additional","affiliation":[{"name":"Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0227-7188","authenticated-orcid":false,"given":"Daniel","family":"Mertens","sequence":"additional","affiliation":[{"name":"Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany;"},{"name":"Cooperation Unit \u201cMechanisms of Leukemogenesis\u201d, German Cancer Research Center, Heidelberg, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith A.","family":"Fox","sequence":"additional","affiliation":[{"name":"Sunesis Pharmaceuticals, Inc., South San Francisco, CA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8397-1886","authenticated-orcid":false,"given":"Klaus-Michael","family":"Debatin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00fcder Hinrich","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Taverna","sequence":"additional","affiliation":[{"name":"Sunesis Pharmaceuticals, Inc., South San Francisco, CA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Seiffert","sequence":"additional","affiliation":[{"name":"Molecular Genetics, German Cancer Research Center, Heidelberg, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9295-5231","authenticated-orcid":false,"given":"Peter","family":"Gierschik","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Toxicology, Ulm University, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany;"},{"name":"Comprehensive Cancer Center Ulm, Ulm University Medical Center, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"2","key":"2022021016291800200_B1","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1097\/HS9.0000000000000175","article-title":"From biology to therapy: the CLL success story","volume":"3","author":"Yosifov","year":"2019","journal-title":"HemaSphere."},{"issue":"5","key":"2022021016291800200_B2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N Engl J Med."},{"issue":"11","key":"2022021016291800200_B3","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol."},{"issue":"2","key":"2022021016291800200_B4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood."},{"issue":"16","key":"2022021016291800200_B5","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood."},{"issue":"6","key":"2022021016291800200_B6","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1172\/JCI24387","article-title":"Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity","volume":"115","author":"Herv\u00e9","year":"2005","journal-title":"J Clin Invest."},{"issue":"7","key":"2022021016291800200_B7","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood-2007-11-125450","article-title":"A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies","volume":"111","author":"Lanemo Myhrinder","year":"2008","journal-title":"Blood."},{"issue":"13","key":"2022021016291800200_B8","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1182\/blood-2008-06-162024","article-title":"Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA","volume":"112","author":"Chu","year":"2008","journal-title":"Blood."},{"issue":"19","key":"2022021016291800200_B9","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood-2009-09-244251","article-title":"Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin","volume":"115","author":"Chu","year":"2010","journal-title":"Blood."},{"issue":"7415","key":"2022021016291800200_B10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"D\u00fchren-von Minden","year":"2012","journal-title":"Nature."},{"issue":"17","key":"2022021016291800200_B11","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood."},{"issue":"15","key":"2022021016291800200_B12","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood."},{"issue":"13","key":"2022021016291800200_B13","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood-2014-08-593137","article-title":"Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma","volume":"125","author":"Sagiv-Barfi","year":"2015","journal-title":"Blood."},{"issue":"9","key":"2022021016291800200_B14","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"2022021016291800200_B15","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.3389\/fimmu.2019.02832","article-title":"Long-term ibrutinib therapy reverses CD8+ T cell exhaustion in B cell chronic lymphocytic leukaemia","volume":"10","author":"Parry","year":"2019","journal-title":"Front Immunol."},{"issue":"8","key":"2022021016291800200_B16","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest."},{"issue":"24","key":"2022021016291800200_B17","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med."},{"issue":"24","key":"2022021016291800200_B18","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia [published correction appears in N Engl J Med. 2014;370(26):2547]","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med."},{"key":"2022021016291800200_B19","doi-asserted-by":"crossref","first-page":"C186","DOI":"10.1158\/1535-7163.TARG-15-C186","article-title":"Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation","volume":"14","author":"Binnerts","year":"2015","journal-title":"Mol Cancer Ther."},{"issue":"17","key":"2022021016291800200_B20","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1074\/jbc.RA119.011946","article-title":"Noncatalytic Bruton\u2019s tyrosine kinase activates PLC\u03b32 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells","volume":"295","author":"Wist","year":"2020","journal-title":"J Biol Chem."},{"issue":"6","key":"2022021016291800200_B21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2018881029","article-title":"IGF1R as druggable target mediating PI3K-\u03b4 inhibitor resistance in a murine model of chronic lymphocytic leukemia","volume":"134","author":"Scheffold","year":"2019","journal-title":"Blood."},{"issue":"8","key":"2022021016291800200_B22","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton\u2019s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood."},{"issue":"6","key":"2022021016291800200_B23","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0318-3","article-title":"PI3K\u03b4 inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia."},{"issue":"5","key":"2022021016291800200_B24","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in\u00a0vitro and in\u00a0vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood."},{"issue":"4","key":"2022021016291800200_B25","doi-asserted-by":"crossref","first-page":"129531","DOI":"10.1016\/j.bbagen.2020.129531","article-title":"Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton\u2019s tyrosine kinase reveals differences in on- and off- target inhibition","volume":"1864","author":"Liclican","year":"2020","journal-title":"Biochim Biophys Acta, Gen Subj."},{"issue":"6","key":"2022021016291800200_B26","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.4049\/jimmunol.138.6.1660","article-title":"Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3","volume":"138","author":"Geppert","year":"1987","journal-title":"J Immunol."},{"issue":"6","key":"2022021016291800200_B27","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1084\/jem.20110308","article-title":"T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse","volume":"208","author":"Moran","year":"2011","journal-title":"J Exp Med."},{"issue":"5","key":"2022021016291800200_B28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell."},{"issue":"19","key":"2022021016291800200_B29","doi-asserted-by":"crossref","first-page":"e121438","DOI":"10.1172\/jci.insight.121438","article-title":"Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies","volume":"3","author":"Ten Hacken","year":"2018","journal-title":"JCI Insight."},{"issue":"10","key":"2022021016291800200_B30","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia."},{"issue":"22","key":"2022021016291800200_B31","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med."},{"issue":"1","key":"2022021016291800200_B32","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol."},{"issue":"3","key":"2022021016291800200_B33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med."},{"issue":"1","key":"2022021016291800200_B34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med."},{"issue":"8","key":"2022021016291800200_B35","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","article-title":"T-cells in chronic lymphocytic leukemia: guardians or drivers of disease?","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia."},{"issue":"4","key":"2022021016291800200_B36","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3324\/haematol.2019.238154","article-title":"Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice","volume":"106","author":"Hanna","year":"2021","journal-title":"Haematologica."},{"issue":"9","key":"2022021016291800200_B37","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood."},{"issue":"2","key":"2022021016291800200_B38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ijc.33212","article-title":"Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients","volume":"148","author":"Fan","year":"2020","journal-title":"Int J Cancer."},{"issue":"4","key":"2022021016291800200_B39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/bloodadvances.2018029058","article-title":"Resistance mechanism for ibrutinib in marginal zone lymphoma","volume":"3","author":"Epperla","year":"2019","journal-title":"Blood Adv."},{"issue":"22","key":"2022021016291800200_B40","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V128.22.1752.1752","article-title":"Noninvasive detection of ibrutinib resistance in non-Hodgkin lymphoma using cell-free DNA","volume":"128","author":"Scherer","year":"2016","journal-title":"Blood."},{"issue":"10","key":"2022021016291800200_B41","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov."},{"key":"2022021016291800200_B42","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1182\/blood-2019-126114","article-title":"Loxo-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations","volume":"134","author":"Gomez","year":"2019","journal-title":"Blood."},{"key":"2022021016291800200_B43","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood-2019-124362","article-title":"LOXO-305: targeting C481S Bruton tyrosine kinase in patients with ibrutinib-resistant CLL","volume":"134","author":"Naeem","year":"2019","journal-title":"Blood."},{"key":"2022021016291800200_B44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-134970","article-title":"LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL\/SLL: results from the phase 1\/2 BRUIN study","volume":"136","author":"Mato","year":"2020","journal-title":"Blood."},{"issue":"9","key":"2022021016291800200_B45","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood."},{"issue":"2","key":"2022021016291800200_B46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2015-02-626754","article-title":"Mechanisms of PD-L1\/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E\u00b5-TCL1 CLL mouse model","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood."},{"issue":"1","key":"2022021016291800200_B47","doi-asserted-by":"crossref","first-page":"E68","DOI":"10.3390\/ijms21010068","article-title":"Harnessing the effects of BTKI on T cells for effective immunotherapy against CLL","volume":"21","author":"Mhibik","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"4","key":"2022021016291800200_B48","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J Immunol."},{"key":"2022021016291800200_B49","first-page":"1","article-title":"Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients","volume":"2021","author":"\u00d6zt\u00fcrk","year":"2021","journal-title":"Leukemia."},{"issue":"29","key":"2022021016291800200_B50","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is\u00a0efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"issue":"14","key":"2022021016291800200_B51","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood-2014-12-619163","article-title":"Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy","volume":"125","author":"de Rooij","year":"2015","journal-title":"Blood."},{"issue":"2","key":"2022021016291800200_B52","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(18)30216-3","article-title":"Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial","volume":"6","author":"Nastoupil","year":"2019","journal-title":"Lancet Haematol."},{"issue":"17","key":"2022021016291800200_B53","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv."},{"issue":"21","key":"2022021016291800200_B54","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/6\/859\/1869813\/bloodbld2021011516.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/6\/859\/1869813\/bloodbld2021011516.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T01:13:59Z","timestamp":1673572439000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/6\/859\/477372\/Evaluation-of-vecabrutinib-as-a-model-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,2,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021011516","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]}}}